Oct 22, 2019 - Four drug/biotech stocks are scheduled to release third-quarter results on Oct 23. Let's see how these companies are placed before their earnings call.
Oct 22, 2019 - Novartis (NVS) beats sales estimates in the third quarter of 2019, driven by robust performance of key drugs and increased contribution from new launches.
Oct 21, 2019 - Does Euronav NV (EURN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Oct 18, 2019 - SLB earnings call for the period ending September 30, 2019.
Oct 18, 2019 - Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Novartis (NVS) reports third-quarter 2019 results.
Oct 17, 2019 - Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.
Oct 17, 2019 - Roche (RHHBY) reports strong sales in the first nine months of 2019 and raises guidance.
Oct 16, 2019 - ASML earnings call for the period ending September 29, 2019.
Oct 14, 2019 - Roche (RHHBY) announces positive late-stage data on Rituxan for the treatment of moderate to severe PV.
Oct 11, 2019 - FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.